Clinical features | Total N = 121 | Dead N = 73 | Alive N = 48 | p value |
---|---|---|---|---|
Female gender | 47 (39%) | 24 (33%) | 23 (48%) | 0.13 |
Age | 60 (49–66) | 60 (49–65) | 61 (52–68) | 0.3 |
Median year of ICU admission (IQR) | 2013 (2010–2015) | 2013 (2010–2016) | 2013 (2010–2015) | 0.86 |
Underlying immunosuppression | ||||
Solid tumors | 36 (30%) | 19 (26%) | 17 (35%) | 0.31 |
Hematological malignancy | 81 (67%) | 52 (71%) | 29 (60%) | 0.24 |
Allogenic SCT | 8 (7%) | 7 (10%) | 1 (2%) | 0.14 |
Acute myeloid leukemia | 17 (14%) | 10 (14%) | 7 (15%) | 1 |
Acute lymphoid leukemia | 9 (7%) | 7 (10%) | 2 (4%) | 0.32 |
Lymphoma | 45 (37%) | 29 (40%) | 16 (33%) | 0.56 |
Myelodysplasia | 6 (5%) | 4 (5.5%) | 2 (4%) | 1 |
Autoimmune disease | 13 (11%) | 7 (10%) | 6 (12.5%) | 0.77 |
HIV infection | 19 (16%) | 11 (15%) | 8 (17%) | 0.80 |
Neutropenia | 58 (49%) | 37 (51%) | 21 (46%) | 0.71 |
ICU features | ||||
SOFA score | 10 (6–15) | 12 (8–16) | 8 (5–14) | 0.011 |
Surgical patient | 25 (21%) | 15 (20%) | 10 (21%) | 1 |
Renal replacement therapy | 71 (61%) | 50 (68.5%) | 22 (46%) | 0.005 |
Invasive mechanical ventilation | 91 (75%) | 61 (85%) | 31 (65%) | 0.015 |
Vasopressors | 66 (54.5%) | 45 (62%) | 21 (44%) | 0.06 |
Candidemia features | ||||
Antifungal prophylaxis | 20 (17%) | 16 (22%) | 4 (8%) | 0.08 |
ICU acquired candidemia | 70 (58%) | 44 (63%) | 26 (54%) | 0.5 |
Candida albicans | 65 (54%) | 39 (53%) | 26 (54%) | 1 |
Candida glabrata | 23 (19%) | 13 (18%) | 10 (21%) | 0.81 |
Candida tropicalis | 13 (11%) | 9 (12%) | 4 (8%) | 0.56 |
Candida krusei | 9 (7%) | 7 (10%) | 2 (4%) | 0.32 |
Candida parapsilosis | 9 (7%) | 5 (7%) | 4 (8%) | 0.74 |
Fluconazole susceptibility | 61 (70%) | 35 (71%) | 27 (69%) | 1 |
Echinocandins susceptibility | 73 (92%) | 39 (89%) | 34 (97%) | 0.22 |
Adequacy of first AF therapy | 78 (90%) | 43 (86%) | 36 (94%) | 0.29 |
CVC removed | 103 (97%) | 61 (98%) | 42 (95.5%) | 0.57 |
Days to first AF therapy (IQR) | 3 (1–3) | 3 (1–3) | 3 (1–3) | 0.45 |
Preemptive antifungal therapy | 27 (22%) | 16 (22%) | 11 (23%) | 1.00 |